7 research outputs found

    SURVEILLANCE DE LA GRIPPE EN FRANCE, SAISON 2016-2017

    No full text
    International audienceThis article summarizes the influenza activity in France for the 2016-17 season.Methods – This report is based on the descriptive analysis of different sources of data on influenza or influenza- like illness collected in mainland France: influenza clinical activity in the community reported by the primary health care network, virological data analysed by reference laboratories, emergency units visits and hospitali- zations for clinical influenza, reporting of acute respiratory infections (ARI) clusters in nursing homes, reporting of severe influenza cases hospitalised in intensive care units (ICU) and mortality data.Results – In mainland France, the 2016-17 season was characterized by a moderate influenza epidemic in the community which started in mid-December, peaked mid-January and lasted 10 weeks. Sub-type A(H3N2) viruses were the almost exclusive circulating influenza viruses. The impact of the influenza epidemic was espe- cially severe among the elderly (65 years old and more) with a high proportion of hospitalisations for influenza among outpatients presenting to emergency ward (16% of 40 000 outpatients) and a high proportion of patients aged above 65 years (69%) among hospitalized patients. This age group accounted for 67% of the 1,479 cases admitted to intensive care. During the epidemic wave, a marked excess mortality estimate at 14,400 deaths attributable to influenza was observed. Over 90% of this excess affected people 75 years old and more.Conclusion – The 2016-17 influenza epidemic was early, moderate, and particularly severe among the elderly. This severity is due to the almost exclusive circulation of A(H3N2) viruses in a context of low vaccine coverage and sub-optimal vaccine effectiveness. It confirms the severity of the disease for the population at risk and strengthens the need for prevention, especially a higher vaccine coverage among people at risk and the implementation of non-pharmaceutical control measures to limit the spread of the virus around cases.Cet article prĂ©sente le bilan Ă©pidĂ©miologique et virologique de l’activitĂ© grippale en France durant la saison 2016-2017.MĂ©thodes – Ce bilan s’appuie sur l’analyse descriptive des donnĂ©es de surveillance de la grippe ou des syndromes grippaux transmises par les rĂ©seaux de mĂ©decine ambulatoire, les analyses virologiques des laboratoires partenaires, les signalements d’épisodes d’infections respiratoires aiguĂ«s (IRA) dans les collec- tivitĂ©s de personnes ĂągĂ©es, la surveillance des passages aux urgences et des hospitalisations codĂ©es grippe, la surveillance des cas graves de grippe hospitalisĂ©s en services de rĂ©animation et les donnĂ©es de mortalitĂ©.RĂ©sultats – L’épidĂ©mie de grippe a dĂ©butĂ© mi-dĂ©cembre et a atteint son pic mi-janvier pour se terminer dĂ©but fĂ©vrier, soit une durĂ©e totale de 10 semaines. Due quasi-exclusivement au virus grippal de type A(H3N2), elle a Ă©tĂ© d’intensitĂ© modĂ©rĂ©e en milieu ambulatoire mais a eu un impact important chez les personnes ĂągĂ©es. Elle a Ă©tĂ© caractĂ©risĂ©e par une part importante d’hospitalisations parmi les passages aux urgences pour syndrome grippal (16% des 40 000 passages) et par une proportion importante des 65 ans et plus parmi les patients hospitalisĂ©s (69%). Cette tranche d’ñge a reprĂ©sentĂ© 67% des 1 479 cas de grippe admis en rĂ©animation. Cette Ă©pidĂ©mie a Ă©galement Ă©tĂ© marquĂ©e par un excĂšs de mortalitĂ© estimĂ© Ă  14 400 dĂ©cĂšs attribuables Ă  la grippe, dont plus de 90% chez les personnes de 75 ans et plus.Conclusion – L’épidĂ©mie de grippe 2016-2017, prĂ©coce et d’intensitĂ© modĂ©rĂ©e, s’est caractĂ©risĂ©e par un impact particuliĂšrement important chez les personnes ĂągĂ©es, liĂ© Ă  la circulation quasi-exclusive de virus A(H3N2) dans un contexte de couverture vaccinale insuffisante et d’efficacitĂ© vaccinale sub-optimale. Cette Ă©pidĂ©mie rappelle la gravitĂ© de la maladie et l’importance de la prĂ©vention, Ă  savoir la vaccination chez les personnes Ă  risque, qui doit ĂȘtre complĂ©tĂ©e de mesures barriĂšres pour limiter la diffusion du virus dans l’entourage des cas

    Surveillance de la grippe en France, saison 2017-2018

    No full text
    International audienceThis article summarizes influenza activity in France for the 2017-2018 season.Methods –This report is based on different sources of data collected in France: clinical influenza-like illness (ILI) in the community reported by the primary health care networks, virological data analysed by reference laboratories, emergency units visits and hospitalizations for clinical influenza, reporting of severe influenza cases hospitalised in intensive care units (ICU), reporting of acute respiratory infections (ARI) clusters in nursing homes, and mortality data.Results –In France, the 2017-18 season started early-December in mainland France, peaked on the last week of December and ended at the end of March, lasting 16 weeks. The epidemic was characterized by an atypical dynamics with two consecutive waves due to the circulation ofA(H1N1)pdm09 followed by B/Yamagata lineage viruses. Its impact was moderate in the community, but high numbers of hospitalizations (>9,700) and severe cases admitted to ICUs (>2,900) were recorded. During the epidemic, a marked excess mortality was observed, with 13,000 deaths attributed to influenza.Conclusion –The 2017-18 influenza epidemic started early and was unusually long, with an atypical dynamics and marked severity. The successive circulation of A(H1N1)pdm09 and B/Yamagata viruses, together with insufficient vaccine coverage and suboptimal vaccine effectiveness, have contributed to this severity. It confirms the high impact of the disease for the population at risk and strengthens the need for prevention especially higher vaccine coverage among people at risk, and the implementation of control measures to limit the spread of the virus around the cases, as well as the utility of early antiviral treatment for subjects at risk.Cet article prĂ©sente le bilan Ă©pidĂ©miologique et virologique de l’épidĂ©mie grippale en France durant la saison 2017-2018.MĂ©thode –Ce bilan s’appuie sur l’analyse descriptive des donnĂ©es de surveillance de la grippe ou des syndromes grippaux transmises par les rĂ©seaux de mĂ©decine ambulatoire, les analyses virologiques des laboratoires partenaires, la surveillance des passages aux urgences et des hospitalisations codĂ©es grippe, la surveillance des cas graves de grippe hospitalisĂ©s en services de rĂ©animation, les signalements d’épisodes d’infections respiratoires aiguĂ«s (IRA) dans les collectivitĂ©s de personnes ĂągĂ©es et les donnĂ©es de mortalitĂ©.RĂ©sultats –L’épidĂ©mie de grippe a dĂ©butĂ© dĂ©but dĂ©cembre en France mĂ©tropolitaine, a atteint son pic au cours de la derniĂšre semaine de dĂ©cembre et s’est terminĂ©e fin mars, soit 16 semaines d’épidĂ©mie. Elle a prĂ©sentĂ© une dynamique atypique, avec deux vagues successives dues Ă  la circulation majoritaire du virus A(H1N1)pdm09 puis Ă  celle du virus B Lignage Yamagata. L’épidĂ©mie a Ă©tĂ© d’intensitĂ© modĂ©rĂ©e en mĂ©decine ambulatoire mais elle a Ă©tĂ© caractĂ©risĂ©e par un nombre Ă©levĂ© d’hospitalisations aprĂšs recours aux urgences pour syndrome grippal (>9 700) et de cas graves admis en rĂ©animation (>2 900). Cette Ă©pidĂ©mie a Ă©galement Ă©tĂ© marquĂ©e par une surmortalitĂ© importante, avec 13 000 dĂ©cĂšs attribuĂ©s Ă  la grippe.Conclusion –L’épidĂ©mie de grippe 2017-2018, prĂ©coce et exceptionnellement longue, a Ă©tĂ© caractĂ©risĂ©e par une dynamique atypique et une importante sĂ©vĂ©ritĂ©, liĂ©es Ă  la circulation successive des virus A(H1N1)pdm09 et B/Yamagata, dans un contexte de couverture vaccinale insuffisante et d’efficacitĂ© vaccinale sous-optimale. Son impact important sur les hospitalisations et la mortalitĂ© rappelle la gravitĂ© de la maladie et l’intĂ©rĂȘt de la prĂ©vention, Ă  savoir la vaccination chez les personnes Ă  risque, complĂ©tĂ©e de mesures barriĂšres afin de limiter la diffusion du virus dans l’entourage des cas, ainsi que l’utilitĂ© d’un traitement antiviral prĂ©coce, particuliĂšrement chez les sujets Ă  risque

    Surveillance de la grippe en France, saison 2017-2018

    No full text
    International audienceThis article summarizes influenza activity in France for the 2017-2018 season.Methods –This report is based on different sources of data collected in France: clinical influenza-like illness (ILI) in the community reported by the primary health care networks, virological data analysed by reference laboratories, emergency units visits and hospitalizations for clinical influenza, reporting of severe influenza cases hospitalised in intensive care units (ICU), reporting of acute respiratory infections (ARI) clusters in nursing homes, and mortality data.Results –In France, the 2017-18 season started early-December in mainland France, peaked on the last week of December and ended at the end of March, lasting 16 weeks. The epidemic was characterized by an atypical dynamics with two consecutive waves due to the circulation ofA(H1N1)pdm09 followed by B/Yamagata lineage viruses. Its impact was moderate in the community, but high numbers of hospitalizations (>9,700) and severe cases admitted to ICUs (>2,900) were recorded. During the epidemic, a marked excess mortality was observed, with 13,000 deaths attributed to influenza.Conclusion –The 2017-18 influenza epidemic started early and was unusually long, with an atypical dynamics and marked severity. The successive circulation of A(H1N1)pdm09 and B/Yamagata viruses, together with insufficient vaccine coverage and suboptimal vaccine effectiveness, have contributed to this severity. It confirms the high impact of the disease for the population at risk and strengthens the need for prevention especially higher vaccine coverage among people at risk, and the implementation of control measures to limit the spread of the virus around the cases, as well as the utility of early antiviral treatment for subjects at risk.Cet article prĂ©sente le bilan Ă©pidĂ©miologique et virologique de l’épidĂ©mie grippale en France durant la saison 2017-2018.MĂ©thode –Ce bilan s’appuie sur l’analyse descriptive des donnĂ©es de surveillance de la grippe ou des syndromes grippaux transmises par les rĂ©seaux de mĂ©decine ambulatoire, les analyses virologiques des laboratoires partenaires, la surveillance des passages aux urgences et des hospitalisations codĂ©es grippe, la surveillance des cas graves de grippe hospitalisĂ©s en services de rĂ©animation, les signalements d’épisodes d’infections respiratoires aiguĂ«s (IRA) dans les collectivitĂ©s de personnes ĂągĂ©es et les donnĂ©es de mortalitĂ©.RĂ©sultats –L’épidĂ©mie de grippe a dĂ©butĂ© dĂ©but dĂ©cembre en France mĂ©tropolitaine, a atteint son pic au cours de la derniĂšre semaine de dĂ©cembre et s’est terminĂ©e fin mars, soit 16 semaines d’épidĂ©mie. Elle a prĂ©sentĂ© une dynamique atypique, avec deux vagues successives dues Ă  la circulation majoritaire du virus A(H1N1)pdm09 puis Ă  celle du virus B Lignage Yamagata. L’épidĂ©mie a Ă©tĂ© d’intensitĂ© modĂ©rĂ©e en mĂ©decine ambulatoire mais elle a Ă©tĂ© caractĂ©risĂ©e par un nombre Ă©levĂ© d’hospitalisations aprĂšs recours aux urgences pour syndrome grippal (>9 700) et de cas graves admis en rĂ©animation (>2 900). Cette Ă©pidĂ©mie a Ă©galement Ă©tĂ© marquĂ©e par une surmortalitĂ© importante, avec 13 000 dĂ©cĂšs attribuĂ©s Ă  la grippe.Conclusion –L’épidĂ©mie de grippe 2017-2018, prĂ©coce et exceptionnellement longue, a Ă©tĂ© caractĂ©risĂ©e par une dynamique atypique et une importante sĂ©vĂ©ritĂ©, liĂ©es Ă  la circulation successive des virus A(H1N1)pdm09 et B/Yamagata, dans un contexte de couverture vaccinale insuffisante et d’efficacitĂ© vaccinale sous-optimale. Son impact important sur les hospitalisations et la mortalitĂ© rappelle la gravitĂ© de la maladie et l’intĂ©rĂȘt de la prĂ©vention, Ă  savoir la vaccination chez les personnes Ă  risque, complĂ©tĂ©e de mesures barriĂšres afin de limiter la diffusion du virus dans l’entourage des cas, ainsi que l’utilitĂ© d’un traitement antiviral prĂ©coce, particuliĂšrement chez les sujets Ă  risque

    Underdetection of cases of COVID-19 in France threatens epidemic control

    No full text
    International audienceAs countries in Europe gradually relaxed lockdown restrictions after the first wave, test–trace–isolate strategies became critical to maintain the incidence of coronavirus disease 2019 (COVID-19) at low levels1,2. Reviewing their shortcomings can provide elements to consider in light of the second wave that is currently underway in Europe. Here we estimate the rate of detection of symptomatic cases of COVID-19 in France after lockdown through the use of virological3 and participatory syndromic4 surveillance data coupled with mathematical transmission models calibrated to regional hospitalizations2. Our findings indicate that around 90,000 symptomatic infections, corresponding to 9 out 10 cases, were not ascertained by the surveillance system in the first 7 weeks after lockdown from 11 May to 28 June 2020, although the test positivity rate did not exceed the 5% recommendation of the World Health Organization (WHO)5. The median detection rate increased from 7% (95% confidence interval, 6–8%) to 38% (35–44%) over time, with large regional variations, owing to a strengthening of the system as well as a decrease in epidemic activity. According to participatory surveillance data, only 31% of individuals with COVID-19-like symptoms consulted a doctor in the study period. This suggests that large numbers of symptomatic cases of COVID-19 did not seek medical advice despite recommendations, as confirmed by serological studies6,7. Encouraging awareness and same-day healthcare-seeking behaviour of suspected cases of COVID-19 is critical to improve detection. However, the capacity of the system remained insufficient even at the low epidemic activity achieved after lockdown, and was predicted to deteriorate rapidly with increasing incidence of COVID-19 cases. Substantially more aggressive, targeted and efficient testing with easier access is required to act as a tool to control the COVID-19 pandemic. The testing strategy will be critical to enable partial lifting of the current restrictive measures in Europe and to avoid a third wave
    corecore